
|Articles|March 1, 2002
Study results point to efficacy of once-daily bimatoprost
Indianapolis-Pooled 6-month data from two multicenter, double-blind, parallel studies demonstrate that once-daily treatment with bimatoprost ophthalmic solution 0.03% (Lumigan, Allergan) is safe and more effective than timolol 0.5% for controlling elevated IOP, said Louis B. Cantor, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
Opus Genetics reaches FDA alignment on phase 3 registrational design for OPGx-LCA5 gene therapy
3
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
4
Port Delivery System Therapies in Retinal Vascular Diseases
5






















